Skip to content

Pharmas Challenged by Product Risk and Philanthropy Fatigue – Covalence Pharmaceutical Industry Report 2008

080909_pharmareport.jpgIncreased attention on product human risk and smaller media coverage of drug donations have challenged Pharmaceuticals’ ethical reputation last year, states a report published today by Geneva-based research firm Covalence — Covalence Pharmaceutical Industry Report 2008. The pharmaceutical industry dropped from the first to the third rank of Covalence all-time EthicalQuote ranking across 10 industries. It has been surpassed by Automobiles & Parts and Technology Hardware that progressed greatly because of their environmental actions. Considering the last 12 months (August 2007 — July 2008) Pharmaceuticals achieved only the 8th rank. This situation raises questions regarding the future of the industry’s public reputation and its global license to operate. Press Release; Report Extract ; Offer & Order form

Publication: Covalence Press Release | Region: Global | Company: Pfizer, Merck & Co, Inc, GlaxoSmithKline, Bristol Myers Squibb, Novartis, Roche, Abbott, Sanofi aventis, Boehringer Ingelheim, Johnson & Johnson, Eli Lilly, Amgen, Astra Zeneca, Schering Plough, Takeda, Wyeth | Source: Covalence

Back To Top